Background
Dilated cardiomyopathy (DCM) is a heart muscle disease characterized by left ventricular (LV) or biventricular dilatation and systolic dysfunction in the absence of either pressure or volume overload or coronary artery disease sufficient to explain the dysfunction.
1 -3 Although previously considered as a rare and orphan disease, contemporary estimates of the prevalence of DCM range from 1/2500 up to 1/250 people. 4 Commonly, the onset of the disease occurs in the third or fourth decade of life with a 3:1 male to female predominance. By time the patients are diagnosed, they often have severe contractile dysfunction and remodelling of both ventricles, reflecting a long period of asymptomatic silent disease progression. However, the implementation of optimal pharmacological and non-pharmacological treatment has dramatically improved the prognosis of DCM 5 with an estimated survival free from death or heart transplantation up to 85% at 10 years. 6, 7 Moreover, the lower prevalence of co-morbidities when compared to most patients with other forms of LV systolic dysfunction suggests that individuals with DCM tend to have fewer non-cardiovascular events. 5 These improved outcomes are paralleled by higher rates of LV reverse remodelling (LVRR) with optimal pharmacological and non-pharmacological treatments. 5 In spite of this therapeutic success, emerging evidence suggests that some patients remain vulnerable to sudden cardiac death (SCD) and refractory heart failure (HF) requiring heart transplant or mechanical circulatory support. 7 This review highlights some important concepts in the clinical management of DCM patients such as the possible LVRR under therapy, the need for continuous individualized long-term follow-up, and the role of genetic testing. Some unresolved issues such as arrhythmic stratification or the genotype-phenotype correlation are also discussed, highlighting potential strategies for diagnosing and treating high-risk subsets of patients with DCM throughout the whole natural history of the disease.
it is often considered under the catch-all heading of 'non-ischaemic HF' with reduced ejection fraction. However, the concept that DCM represents a family of diseases characterized by complex interactions between environment and genetic predisposition is gaining prominence as the clinical impact of a precise diagnosis is better appreciated. 8, 9 The term 'idiopathic DCM' is often used in clinical practice and in some series accounts for 20-30% of non-ischaemic HF. However, the approach to a patient with non-ischaemic DCM rarely seeks reversible factors other than hypertension, valve disease, and congenital heart disease ( Figure 1) . Examples of commonly overlooked or underappreciated reversible triggers for LV dysfunction include sustained supraventricular arrhythmias or very frequent ventricular ectopic beats, which can lead to tachycardia-induced cardiomyopathy; substance abuse (e.g. alcohol, cocaine); acute emotional stress or chemotherapies that cause catecholamine or toxin-induced cardiomyopathies; and systemic autoimmune disorders (e.g. Churg-Strauss syndrome and sarcoidosis). New-onset HF with LV dysfunction occurring during pregnancy or the post-partum period could identify a peripartum cardiomyopathy. Confirmation of active myocarditis as the cause of recent onset severe HF (Figure 2) is particularly important as it may require investigations (e.g. endomyocardial biopsy) that are rarely performed in some health care settings. 10 Accordingly, a comprehensive integrated approach, including third level diagnostic tools, should be systematically implemented in clinical practice to remove every possible reversible cause through specific therapeutic interventions ( Table 1) . This issue appears essential to promote LVRR and subsequent outcome improvement.
Identification of genetic causes of dilated cardiomyopathy
When obvious acquired factors have been excluded, a genetic basis for DCM becomes more likely (Figure 3) , particularly when there is a family history of the disease. 2 Familial screening should be systematically performed to obtain an early diagnosis in relatives as this facilitates prompt prophylactic therapy in early or preclinical disease.
11 Importantly, a negative family history does not rule out a genetic form of DCM as de novo mutations can be responsible for sporadic forms.
Genetic forms of DCM are also suggested by the presence of clinical traits, sometimes referred to as diagnostic red flags 12 ( Table 2) . Rare, but important signs and symptoms that suggest specific forms of multisystem disease or specific genotypes are abnormal skin pigmentation, skeletal myopathy, and neurosensory disorders (e.g. deafness, blindness).
12
In most epidemiological studies, the proportion of patients with genetically determined DCM is substantially underestimated due to variable clinical presentation, incomplete disease penetrance, and the lack of specific phenotypes. However, contemporary series using genetic screening suggest that up to 40% of DCM is genetically determined. 4 Most patients with familial DCM have autosomal dominant inheritance, but X-linked, autosomal recessive and maternal transmission (as in mitochondrial disorders) are recognized in isolated cardiac disease and in the context of multiorgan . DMD, FLNC, NEXN, LDB3) . Of note, the DMD gene (encoding for dystrophin) is involved in muscular dystrophy patients and X-linked familial DCM in the absence of overt skeletal muscle disease. 4 Although electrocardiographic findings in DCM are generally non-specific, DMD-related DCM may represent an exception as it is frequently characterized by a posterolateral or inferolateral 'pseudonecrosis' pattern. Echocardiographic and cardiac magnetic resonance (CMR) evaluations usually reveal posterolateral akinesia with late gadolinium enhanced (LGE)-based myocardial scar. Mutations in the DES gene (encoding for desmin) cause skeletal myopathy, cardiac disease with variable cardiomyopathy phenotypes, including DCM and restrictive cardiomyopathy or a combination of the two.
15,16
Mutations in the LMNA gene (encoding lamin A/C) are a cause of familial DCM characterized by cardiac conduction disturbances (atrioventricular block) with elevated serum creatine kinase levels and in some cases skeletal muscle involvement (limb-girdle or Emery-Dreifuss muscular dystrophy). 17 Lamin A/C mutations also convey an increased risk of life-threatening ventricular arrhythmias irrespective of the severity of LV dysfunction and dilatation. 17 Other forms of DCM increasingly grouped under the heading of arrrhythmogenic cardiomyopathies are also characterized by a propensity to ventricular arrhythmia. These include diseases caused by mutations in genes encoding desmosomal proteins, which are classically linked to arrhythmogenic right ventricular cardiomyopathy but have now emerged as a cause of isolated DCM.
18 -20 Mutations in the FLNC gene (encoding for filamin C) have more recently been described as also associated with arrhythmogenic phenotypes of DCM. 21 Mutations in genes encoding for sarcomere (MYH7, ACTC1, TNNT2, MYH6, and MYBPC3) and sodium ion channels (RYR2 and SCN5A) may also be associated with DCM 22 with current widely unknown genotype-phenotype correlations.
Specific phenotypes of dilated cardiomyopathy
Recently, a position statement of the European Society of Cardiology identified two specific phenotypes of preclinical or early stage DCM: arrhythmic DCM and the hypokinetic non-DCM. 3 The latter could often be the result of an early diagnosis of DCM and a timely management, which in turn can lead to favourable long-term outcome. Nonetheless, the association with specific features such as familial history of SCD in arrhythmic DCM and severe diastolic dysfunction or non-sustained ventricular arrhythmias in hypokinetic non-DCM, can indicate distinct genotypes with a less favourable course that require focused follow-up and more aggressive therapeutic strategies such as implantable cardioverter-defibrillator (ICD) implantation.
19,23
Figure 1 Aetiologic characterization of dilated cardiomyopathy (DCM). iDCM, idiopathic dilated cardiomyopathy.
The cornerstones of clinical management of dilated cardiomyopathy during follow-up Dilated cardiomyopathy as a dynamic disease: left ventricular reverse remodelling and the importance of follow-up
Dilated cardiomyopathy has long been considered to be an irreversible condition. However, in recent years several studies revealed that almost 40% of patients experience a significant LVRR when treated with evidence-based pharmacological and device treatments. 6 LVRR is one of the main determinants of prognosis in DCM and should be considered a major goal in approaching newly diagnosed cases. In the absence of specific treatments, the medical management of DCM is based largely on conventional therapy with angiotensin-converting enzyme inhibitors/angiotensin receptor blockers, beta-blockers and mineralocorticoid receptor antagonists. 24 In patients with LV dyssynchrony manifested by left bundle branch block (LBBB), cardiac resynchronization therapy (CRT) can induce LVRR, sometimes with normalization of LV size and systolic function. 25, 26 Even when there is improvement in LV dysfunction, the potential for later decline in systolic function remains, despite uninterrupted treatment.
11 This issue emphasizes the pivotal role not only of an accurate and complete initial diagnostic evaluation but also of continuous therapy and individualized, long-term surveillance to recognize and treat the first signs of late disease progression (Table 3, Figure 4 ).
Other markers of disease severity and progression
The process of LVRR may take up to 2 years following diagnosis. 6 The following aspects have been demonstrated as influencing the . course and the prognosis of the disease and the likelihood of LVRR in the early stages and should be hence systematically assessed:
• Right ventricular function at diagnosis is an important prognostic feature in DCM. 27 The recovery of right ventricular function under therapy is frequent and can be observed already at 6 months. It precedes LVRR, and is emerging as an early therapeutic target and an independent prognostic predictor. 28 Improvement in right ventricular function is also described in CRT recipients as a secondary expression of haemodynamic improvement very early after resynchronization, with consequently favourable survival rates. 29 In contrast, the development of right ventricular dysfunction during long-term follow-up is an expression of structural disease progression and portends a negative outcome. 28 • Functional mitral regurgitation conveys important prognostic implications. Moderate to severe mitral regurgitation at diagnosis or persistent mitral regurgitation despite optimal medical treatment or CRT is associated with poorer outcomes. 29, 30 Patients with DCM and haemodynamically important mitral regurgitation may require invasive therapeutic strategies such as percutaneous repair of the mitral valve, mechanical circulatory support, or even heart transplantation.
• LBBB is a frequent electrocardiographic marker at diagnosis and is negatively associated with the likelihood of LVRR. 6 Importantly, the development of new LBBB during follow-up is a strong independent prognostic predictor of all-cause mortality. 31 Of note, CRT was shown to reduce the risk induced by LBBB, specifically in DCM patients, 25, 26 and should timely be considered after LBBB development during follow-up.
• The onset of atrial fibrillation during the follow-up is a sign of structural disease progression and negatively impacts the prognosis of these patients, despite effective treatments. 32 The implications of these observations are that a multiparametric approach to diagnosis and long-term follow-up, not limited to LV systolic function and size alone, appears essential to improve the quality of clinical management of DCM patients ( Figure 5) . 
Specific aspects in the clinical management of dilated cardiomyopathy

Re-classification of dilated cardiomyopathy during long-term follow-up
Modern management of HF has increased the survival rates of DCM and has resulted in long periods of clinical stability. function or an increased ventricular arrhythmic burden can be caused not only by DCM progression but also by the development of new co-pathologies. Therefore, the possible presence of coronary artery disease, hypertensive heart disease, structural valve disease, or acute myocarditis should be systematically ruled out during the follow-up ( Table 1) .
Paediatric dilated cardiomyopathy
Although rare, DCM is the predominant cause of cardiomyopathy in children. The prevalence is approximately 1:170 000 in the United States 34 and the outcomes for children with DCM are poor, even in the presence of baseline characteristics of an early stage, as compared to adults. 35 The causes of this particular severe phenotype of the disease in paediatric age remain poorly characterized. The generally poorer prognosis in paediatric DCM means that more aggressive therapeutic interventions including ICD implantation and heart transplant list are more frequent in the young.
35
The role of cardiac magnetic resonance CMR is emerging as a fundamental tool for diagnostic purposes and prognostic stratification in patients presenting with LV dysfunction of uncertain origin. CMR represents the gold standard for the assessment of biventricular dimensions and function. Tissue characterization and the distribution of scar aid the identification of secondary causes of DCM such as coronary occlusion, 36 and approximately one-third of DCM cases have a distinctive mid-wall distribution, more frequently within the septal wall. 37 LGE presence, . . patterns and quantification may also help to assess the risk for malignant ventricular arrhythmias and the probability of LVRR. 37 -39 Future multicentre and prospective studies are required to confirm the role of CMR in the prognostic stratification of DCM, especially when defining the arrhythmic risk of those patients. Currently, no guidelines mention CMR as a tool for arrhythmic prognostication in DCM patients.
Endomyocardial biopsy
The role of endomyocardial biopsy in diagnosing heart muscle disorders is controversial due to the invasiveness of the procedure and its poor sensitivity in certain scenarios. Contemporary cardiovascular imaging is also promoted as an alternative to tissue biopsy in some circumstances. Although a broader use to improve the diagnosis of myocarditis and inflammatory cardiomyopathy has recently been proposed, 40 many statements reserved the indications to endomyocardial biopsy for selected cases. 10 In a patient with newly diagnosed DCM, endomyocardial biopsy is reasonable when there is a high probability of a specific diagnosis which can be confirmed only in myocardial samples and is amenable to therapy that has the potential to change . (Figure 2) , the contemporary presence of a hypertrophic and dilated left ventricle (for example in end-stage hypertrophic cardiomyopathy), cardiac amyloidosis, sarcoidosis, or haemochromatosis.
10
Genetic testing in dilated cardiomyopathy
Various position statements recommend testing of a proband (the first or most clearly affected person in a family with a cardiomyopathy) when there is clear familial disease or in the presence of diagnostic red flags suggestive of a genetic disorder. The rationale is to confirm the diagnosis, to identify individuals who are at high risk of arrhythmias and to facilitate cascade screening within families. 43 However, restriction of genetic testing to familial cases has recently been questioned following studies showing that the yield of genetic testing is similar between familial and non-familial cases 44 and the presence of titin truncating mutations in 10-15% of sporadic DCM. 45 Genotype-phenotype interactions are still an unmet issue of translational research and the effects of mutations on the mechanisms of disease expression remain largely unknown. Extreme genetic heterogeneity and variable penetrance prohibited robust genotype-phenotype correlation studies and actually genotype information does not strongly impact on clinical management of DCM. Nevertheless, despite the complex genetic architecture of DCM, an increasing number of actionable prognostic genotype-phenotype associations are emerging. For carriers of LMNA mutations, the presence of non-sustained ventricular tachycardia, LV impairment, male gender, and non-missense mutations (nonsense, frameshift insertion-deletions, or splicing) are reported to be independent risk factors for malignant ventricular arrhythmias. Consequently, primary preventive ICD implantation is recommended in patients with high-risk features. An increased risk of SCD is also reported in individuals with DCM caused by mutations in DES, RBM20, PLN, and filamin C truncating mutations. 21 Multicentre studies are needed to fill the gap in knowledge of the multiple and heterogeneous genotype-phenotype correlations promoting the onset of DCM in carriers of disease-related gene mutations. Moreover, it appears pivotal to clarify the influence of environmental factors (i.e. strenuous exercise) on still unknown predisposing gene variants, including the role of non-coding DNA regions and RNAs, in order to establish a complete expression of disease.
Arrhythmic risk stratification
Primary prevention of SCD with ICD implantation significantly ameliorated overall mortality in patients with ischaemic HF 24 but in non-ischaemic DCM, randomized clinical trials such as SCD-HeFT, DEFINITE and the more recent DANISH trial have failed to demonstrate a clear survival benefit. 46 for primary prevention with an ICD are based on a simplistic assessment of LV function and HF symptoms. 25, 46 However, it is clear that the risk of ventricular arrhythmia varies according to aetiology. For example, it has been reported that patients with DCM secondary to systemic hypertension (usually older and with more co-morbidities) have lower arrhythmic event rates during follow-up. 49 Conversely, younger patients with some of the more malignant genetic forms of DCM may have a greater survival benefit from ICD implantation. 5, 47, 48 In addition, only one-third of DCM cases admitted with current criteria for ICD still fulfill indications for implantation 6 months after initiation of optimal medical treatment. 7 Accordingly, a wait-and-see period of 3 to 9 months is currently recommended to increase the appropriateness of ICD therapy. 25 However, in a large series of recent onset DCM, approximately 2% of patients died suddenly in the first 6 months after diagnosis. 50 Patients presenting with severe LV dilatation, longer QRS and long duration of symptoms were at higher risk, while LV ejection fraction alone did not show any association with early events. 50 It is clear that alternative and more reliable multiparametric models that incorporate aetiology, CMR, and biomarkers such as natriuretic peptides are required.
Conclusions and future perspectives
In recent decades, long-term survival of DCM patients has markedly increased. Several strategies have contributed to this improvement, including early diagnosis through systematic familial screening, more refined phenotyping at the onset of disease, implementation of evidence-based medical and device treatments, and rigorous long-term individualized follow-up. However, DCM remains the most common cause of heart transplant and one of the leading causes of death in the Western world. Further progress in reducing morbidity and mortality requires systematic use of diagnostic tools including genetic testing, improved risk modelling, and a deeper investigation of the basic mechanisms underlying the disease.
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